Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Filing Type: Form 10-Q
Period Ended: March 31, 2011
Business Overview: A specialty pharmaceutical company focused on immune system enhancing technologies. Key products include Ampligen® (investigational for Chronic Fatigue Syndrome and as an influenza vaccine adjuvant) and Alferon N Injection® (FDA-approved for genital warts, currently not in commercial production due to inventory expiration and facility upgrades).
Key Financial Metrics
| Metric (in thousands) | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $42 | $32 |
| Operating Loss | $(3,590) | $(4,073) |
| Net Loss | $(866) | $(5,380) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.04) |
| Cash and Cash Equivalents | $2,247 | $50,723 (End of Q1 2010) |
| Total Assets | $50,329 | $51,680 (Dec 31, 2010) |
| Total Liabilities | $4,714 | $5,733 (Dec 31, 2010) |
| Stockholders' Equity | $45,615 | $45,947 (Dec 31, 2010) |
Liquidity: As of March 31, 2011, the company held approximately $42.8 million in Cash, Cash Equivalents, and Marketable Securities. Net cash used in operating activities was $1.8 million for the quarter.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by 84% (from $5.38 million to $0.87 million) compared to Q1 2010.
- Non-Cash Gains: The reduction in loss was significantly driven by a $301,000 non-cash gain from the revaluation of redeemable warrants (compared to a $1.34 million loss in Q1 2010) and $2.27 million in proceeds from the sale of New Jersey state net operating loss (NOL) carryforwards.
- Expense Reductions: Research and Development expenses decreased by 18% ($356,000) and General and Administrative expenses decreased by 9% ($170,000), primarily due to reduced clinical costs and legal fees.
- Revenue Growth: Revenues increased 31% to $42,000, driven by a 29% increase in patients in the Ampligen® Cost Recovery Program.
- Investment Income: Interest and other income increased 441% to $157,000 due to a diverse portfolio of investments.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Ampligen® Status: The FDA granted a one-year extension to respond to a Complete Response Letter (CRL) regarding the NDA for Chronic Fatigue Syndrome. The company estimates a new Phase III study will cost between $7.2 million and $11.1 million and take 18 months to three years.
- Alferon N Injection®: Commercial sales remain halted. The company is upgrading its New Brunswick facility and expects to resume manufacture potentially in mid-to-late 2011, pending FDA review of new lots.
- Alferon® LDO: The FDA lifted a clinical hold on a Phase II study for influenza prophylaxis in December 2010; site selection is underway.
- Japan Partnership: The Material Evaluation Agreement (MEA) with Biken regarding Ampligen® as an influenza vaccine adjuvant expired in September 2010. Biken declined to extend the agreement, citing safety concerns regarding a rat toxicity study. Hemispherx disputes these findings and is seeking alternative partners in Japan.
Risks and Contingencies
- Capital Requirements: The company has an accumulated deficit of approximately $218.6 million. It may require additional financing, which could result in significant dilution. Only ~32.2 million shares remain authorized but unissued.
- Legal Proceedings:
- JCI Litigation: Hemispherx was awarded $188 million plus interest against Johannesburg Consolidated Investments; enforcement is ongoing in South Africa.
- Cato Capital: Lawsuit seeking up to $9.83 million in placement fees; motions to dismiss are pending.
- MidSouth Capital: Counterclaims and appeals regarding financing fees are pending in the Eleventh Circuit Court of Appeals.
- Manufacturing: No long-term agreements exist for certain raw materials or third-party formulation services for Alferon N Injection®.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the ~$42.8 million cash position against the estimated $7.2M–$11.1M cost for the required Ampligen® Phase III study and ongoing operational burn.
- Alferon® Production Timeline: Confirm the status of facility upgrades and FDA review for new Alferon N Injection® lots to assess the likelihood of revenue resumption in 2011.
- Japan Partnership: Monitor progress in securing a new Japanese partner to replace Biken for the influenza adjuvant program.
- Legal Enforcement: Track the status of the $188 million judgment against JCI in South Africa to determine collectability.
- Share Authorization: Assess the impact of the limited number of unissued shares (~32.2 million) on future fundraising capabilities.